Marketdash
Back to Stock Market News

Dow Slips Over 100 Points as Pending Home Sales Beat Expectations

MarketDash Editorial Team
3 hours ago
U.S. stocks opened lower Monday with the Dow falling more than 100 points, while pending home sales jumped 3.3% in November, crushing market expectations. Energy stocks led gains as materials dragged, and several pharmaceutical stocks saw dramatic swings on clinical trial news.

Monday brought a dose of reality to U.S. markets after the holiday break, with stocks sliding lower across the board despite some surprisingly positive housing data.

The Dow Jones fell 0.25% to 48,591.37 following the market open, while the NASDAQ slipped 0.55% to 23,464.42. The S&P 500 dropped 0.34% to 6,906.41, extending the cautious tone that's been hanging over markets heading into year-end.

Sector Moves Tell the Story

Energy shares bucked the trend, rising 0.6% on Monday as oil prices climbed. That made energy the day's clear winner, which makes sense given crude oil jumped 2.5% to $58.13 per barrel.

On the flip side, materials stocks took the biggest hit, falling 1.1%. That sector got dragged down by a brutal day for commodities. Gold tumbled 4.2% to $4,360.50, silver dropped 6.8% to $71.945, and copper fell 4.6% to $5.5725. When metals get hammered like that, materials stocks tend to follow right along.

Housing Market Shows Unexpected Strength

Here's the headline that should have market watchers paying attention: U.S. pending home sales jumped 3.3% month-over-month in November, following a revised 2.4% gain in October. That crushed market estimates of just a 1% gain.

Pending home sales track signed contracts for existing home purchases, so they're a forward-looking indicator of where the housing market is headed. A gain this strong suggests more resilience than economists expected, despite elevated mortgage rates and affordability challenges.

Big Movers

The individual stock action was wild, particularly in biotech. Mereo BioPharma Group plc (MREO) absolutely cratered, dropping 89% to $0.2436 after announcing its Phase 3 ORBIT and COSMIC Studies for setrusumab in Osteogenesis Imperfecta failed to achieve statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates. That's the kind of news that obliterates a biotech stock.

Ultragenyx Pharmaceutical Inc. (RARE) also got crushed, falling 41% to $20.10 after the company and its partner Mereo Biopharma announced the same failed Phase 3 results for setrusumab in osteogenesis imperfecta.

On the winning side, CCSC Technology International Holdings Limited (CCTG) skyrocketed 93% to $0.2516, while Brand Engagement Network, Inc. (BNAI) surged 77% to $2.1200 after finalizing a Vendor Services Project Agreement with a prominent global advertising agency. Society Pass Incorporated (SOPA) gained 58% to $2.88 after announcing the launch of TMG Social.

ECD Automotive Design, Inc. (ECDA) fell 35% to $0.7521 in Monday trading.

Global Markets

European markets showed more stability than their U.S. counterparts. The eurozone's STOXX 600 gained 0.1%, while Spain's IBEX 35 Index and France's CAC 40 both rose 0.1%. London's FTSE 100 added 0.1%, though Germany's DAX 40 slipped 0.1%.

Asian markets closed mostly lower on Monday. Japan's Nikkei 225 fell 0.44%, Hong Kong's Hang Seng Index dropped 0.71%, and India's BSE Sensex declined 0.41%. China's Shanghai Composite managed a small gain of 0.04%.

The market's subdued tone heading into the final stretch of the year reflects ongoing uncertainty about Federal Reserve policy, economic growth prospects, and whether the strong 2024 rally can maintain momentum into 2025.

Back to Stock Market News

Dow Slips Over 100 Points as Pending Home Sales Beat Expectations

MarketDash Editorial Team
3 hours ago
U.S. stocks opened lower Monday with the Dow falling more than 100 points, while pending home sales jumped 3.3% in November, crushing market expectations. Energy stocks led gains as materials dragged, and several pharmaceutical stocks saw dramatic swings on clinical trial news.

Monday brought a dose of reality to U.S. markets after the holiday break, with stocks sliding lower across the board despite some surprisingly positive housing data.

The Dow Jones fell 0.25% to 48,591.37 following the market open, while the NASDAQ slipped 0.55% to 23,464.42. The S&P 500 dropped 0.34% to 6,906.41, extending the cautious tone that's been hanging over markets heading into year-end.

Sector Moves Tell the Story

Energy shares bucked the trend, rising 0.6% on Monday as oil prices climbed. That made energy the day's clear winner, which makes sense given crude oil jumped 2.5% to $58.13 per barrel.

On the flip side, materials stocks took the biggest hit, falling 1.1%. That sector got dragged down by a brutal day for commodities. Gold tumbled 4.2% to $4,360.50, silver dropped 6.8% to $71.945, and copper fell 4.6% to $5.5725. When metals get hammered like that, materials stocks tend to follow right along.

Housing Market Shows Unexpected Strength

Here's the headline that should have market watchers paying attention: U.S. pending home sales jumped 3.3% month-over-month in November, following a revised 2.4% gain in October. That crushed market estimates of just a 1% gain.

Pending home sales track signed contracts for existing home purchases, so they're a forward-looking indicator of where the housing market is headed. A gain this strong suggests more resilience than economists expected, despite elevated mortgage rates and affordability challenges.

Big Movers

The individual stock action was wild, particularly in biotech. Mereo BioPharma Group plc (MREO) absolutely cratered, dropping 89% to $0.2436 after announcing its Phase 3 ORBIT and COSMIC Studies for setrusumab in Osteogenesis Imperfecta failed to achieve statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates. That's the kind of news that obliterates a biotech stock.

Ultragenyx Pharmaceutical Inc. (RARE) also got crushed, falling 41% to $20.10 after the company and its partner Mereo Biopharma announced the same failed Phase 3 results for setrusumab in osteogenesis imperfecta.

On the winning side, CCSC Technology International Holdings Limited (CCTG) skyrocketed 93% to $0.2516, while Brand Engagement Network, Inc. (BNAI) surged 77% to $2.1200 after finalizing a Vendor Services Project Agreement with a prominent global advertising agency. Society Pass Incorporated (SOPA) gained 58% to $2.88 after announcing the launch of TMG Social.

ECD Automotive Design, Inc. (ECDA) fell 35% to $0.7521 in Monday trading.

Global Markets

European markets showed more stability than their U.S. counterparts. The eurozone's STOXX 600 gained 0.1%, while Spain's IBEX 35 Index and France's CAC 40 both rose 0.1%. London's FTSE 100 added 0.1%, though Germany's DAX 40 slipped 0.1%.

Asian markets closed mostly lower on Monday. Japan's Nikkei 225 fell 0.44%, Hong Kong's Hang Seng Index dropped 0.71%, and India's BSE Sensex declined 0.41%. China's Shanghai Composite managed a small gain of 0.04%.

The market's subdued tone heading into the final stretch of the year reflects ongoing uncertainty about Federal Reserve policy, economic growth prospects, and whether the strong 2024 rally can maintain momentum into 2025.